Reliability at the lower limits of HIV-1 RNA quantification in clinical samples: A comparison of RT-PCR versus bDNA assays

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Lubelchek, Ronald J ^a,b,c   Max, Blake ^b   Sandusky, Caroline J ^c   Hota, Bala ^a,b,c   Barker, David E ^a,b,c  

^a Jr Hospital of Cook County   (United States)

^b Ruth M Rothstein CORE Center   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; CD4 ANTIGEN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BRANCHED CHAIN DNA ASSAY; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; QUANTITATIVE STUDY; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; VIREMIA; VIRUS LOAD; BIOSYNTHESIS; BRANCHED DNA SIGNAL AMPLIFICATION ASSAY; COHORT ANALYSIS; COMPARATIVE STUDY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; RETROSPECTIVE STUDY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTIGENS, CD4; BRANCHED DNA SIGNAL AMPLIFICATION ASSAY; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 67650308688     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006008     Document Type: Article

References (16)

1. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, et al. (1997) Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126(12): 946-954.
2. Department of Health and Human Services (2006) Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents.
3. Nolte FS, Boysza J, Thurmond C, Clark WS, Lennox JL (1998) Clinical comparison of enhanced-sensitivity branched-DNA assay and reverse transcription-PCR for quantitation of Human Immunodeficiency Virus type 1 RNA in plasma. J Clin Micro 36(3): 716-720.
4. Elbeik T, Charlebois E, Nassos P, Kahn J, Hecht F, et al. (2000) Quantitative and cost comparison of ultrasensitive Human Immunodeficiency Virus type 1 RNA viral load assays: Bayer bDNA versions 3.0 and 2.0 and Roche PCR Amplicor Monitor version 1.5. J Clin Micro 38(3): 1113-1120.
5. Galli R, Merrick L, Friesenhahn M, Ziermann (2005) Comprehensive comparison of the VERSANT HIV-1 RNA (bDNA) and COBAS AMPLICOR HIV-1 MONITOR 1.5 assays on 1000 clinical specimens. J Clin Virol 34: 245-252.
6. Elbeik T, Alvord WG, Trichavaroj R, de Souza M, Dewar R, et al. (2002) Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5. JAIDS 29: 330-339.
7. Murphy DG, Cote L, Fauvel M, Rene P, Vincelette (2000) Multicenter comparison of Roche COBAS Amplicor Monitor version 1.5, Organon Teknika NucliSense QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Micro 38: 4034-4041.
8. Peter JB, Blum R (2002) Monitoring HIV viral loads in the United States: recent trends and methodologies. JAIDS 30(2): 261-262.
9. Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, et al. (2005) Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 293: 817-829.
10. Sungkanuparph S, Overton ET, Seyfried W, Groger R, Fraser V, et al. (2005) Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 41: 1326-1332.
11. Murphy R, Berzins B, Leake A, Till M, Stosor V, et al. (2005) Effect of Plasma Preparation Tubes (PPT) vs. standard EDTA tubes on viral "blips" in patients with optimally suppressed plasma HIV-1 RNA. Abstract 738. 12th Conference on Retroviruses and Opportunistic Infections. Feb. 22nd-25th, Boston.
12. Division of Antiviral Drug Products, Office of Drug Evaluation IV, Center for Drug Evaluation and Research (CDER), Food and Drug Administration. Guidance for Industry: Antiretroviral Drugs Using Plasma HIV RNA Measurements - Clinical Considerations for Accelerated and Traditional Approval. Accessed June 26, 2006. Available at: http://www.fda.gov/cder/guidance/3647fnl.pdf.
13. Giordano M, Kelleher T, Colonno RJ, Lazzarin A, Squires K (2006) The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and inappropriateness of cross-study comparisons. J Clin Virol 35: 420-425.
14. Ribaudo H, Lennox J, Currier J, Kuritzkes D, Gulick R, et al. (2009) Virologic failure endpoint definition in clinical trials: is using HIV-1 RNA threshold <200 copies/ml better than <50 copies/ml? An analysis of ACTG studies. Abstract 580. 16th Conference on Retroviruses and Opportunistic Infections. Feb 8th-11th, Montreal.
15. Salimnia H, Moore EC, Crane LR, MacArthur RD, Fairfax MR (2005) Discordance between viral loads determined by Roche COBAS AMPLICOR Human Immunodeficiency Virus type 1 Monitor (version 1.5) standard and ultrasensitive assays caused by freezing patient plasma in centrifuged Becton-Dickinson Vacutainer brand Plasma Preparation Tubes. J Clin Micro 43: 4635-4639.
16. Nettles RE, Kieffer TL, Simmons RP, Cofrancesco J, Moore RD, et al. (2004) Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Inf Dis 39: 1030-1037.